The offering’s potential dilution to existing shareholders sent Verenium’s shares down as much as 25% during the session.
The company, which develops and commercializes cellulosic ethanol, and specialty enzymes for applications within the biofuels, industrial, and animal health markets, is based in Cambridge, Massachusetts.
In a statement, Verenium says each share consists of one common share and a warrant to purchase 0.4
